Author:
Chen Lu,Zhang Xiaoqin,Ou Yaqing,Liu Maoyu,Yu Dongke,Song Zhiheng,Niu Lihong,Zhang Lijuan,Shi Jianyou
Abstract
Programmed necrosis is a new modulated cell death mode with necrotizing morphological characteristics. Receptor interacting protein 1 (RIPK1) is a critical mediator of the programmed necrosis pathway that is involved in stroke, myocardial infarction, fatal systemic inflammatory response syndrome, Alzheimer’s disease, and malignancy. At present, the reported inhibitors are divided into four categories. The first category is the type I ATP-competitive kinase inhibitors that targets the area occupied by the ATP adenylate ring; The second category is type Ⅱ ATP competitive kinase inhibitors targeting the DLG-out conformation of RIPK1; The third category is type Ⅲ kinase inhibitors that compete for binding to allosteric sites near ATP pockets; The last category is others. This paper reviews the structure, biological function, and recent research progress of receptor interaction protein-1 kinase inhibitors.
Subject
Pharmacology (medical),Pharmacology
Reference101 articles.
1. Type II inhibitors targeting CDK2;Alexander;ACS Chem. Biol.,2015
2. Discovery of simplified benzazole fragments derived from the marine benzosceptrin B as necroptosis inhibitors involving the receptor interacting protein Kinase-1;Benchekroun;Eur. J. Med. Chem.,2020
3. Birinapant (TL32711), a bivalent SMAC mimetic, targets TRAF2-associated cIAPs, abrogates TNF-induced NF-κB activation, and is active in patient-derived xenograft models;Benetatos;Mol. Cancer Ther.,2014
4. Characterization of GSK'963: A structurally distinct, potent and selective inhibitor of RIP1 kinase;Berger;Cell Death Discov.,2015
5. Cutting edge: RIP1 kinase activity is dispensable for normal development but is a key regulator of inflammation in SHARPIN-deficient mice;Berger;J. Immunol.,2014
Cited by
15 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献